Nurix Therapeutics Inc (NAS:NRIX)
$ 25.36 +0.14 (+0.56%) Market Cap: 2.63 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 6.54 GF Score: 61/100

Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 20, 2026 / 05:30 PM GMT
Release Date Price: $16.42 (+7.74%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NRIX.OQ - Nurix Therapeutics Inc
Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference
May 20, 2026 / 05:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Well, let's get started. Good afternoon, everyone. Welcome back from lunch. I'm Brian Abrams, Senior Biotech Analyst here at RBC Capital Markets.

We're really pleased to have our next featured company, Nurx Therapeutics, represented by their CEO, Arthur Sands, and their CBO, Jason Kantorx.

Great. Thanks for being here. Thanks, Brian. Thanks for being here.

So maybe let's start. A little bit bigger picture on your lead program, Beckstag.

Tell us what your latest view is on the potential advantages that BTK degraders can have in the CLL space relative to the currently available inhibitors. What's out there today? And what's been your view as to the strongest
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot